Mast Cell Leukemia Clinical Trial
Official title:
An External Control, Observational, Retrospective Study Assessing the Effect of Avapritinib Compared With Best Available Therapy for Patients With Advanced Systemic Mastocytosis
Verified date | December 2021 |
Source | Blueprint Medicines Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
BLU-285-2405 is a multi-center, synthetic control, observational and retrospective study designed to compare clinical outcomes for avapritinib compared with best available therapy for patients with AdvSM.
Status | Completed |
Enrollment | 317 |
Est. completion date | October 4, 2021 |
Est. primary completion date | October 4, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria for Patients in the External Control Arm: 1. Diagnosed with AdvSM, with known subtype including SM-AHN, ASM, or MCL 2. Received at least one line of systemic therapy for AdvSM, which may include but not limited to regimens containing: Midostaurin Cytoreductive therapy: cladribine, interferon alpha, azacitidine, decitabine Selective TKIs: imatinib, nilotinib, dasatinib Hydroxyurea Antibody therapy: brentuximab vedotin 3. Adult (=18 years of age) at the initiation of first systemic line of therapy at the participating site 4. Had an index date at least 3 months prior to the start of data collection (in order to include patients with at least 3 months of follow-up after index date), unless date of death occurred less than three months from index date 5. Had an approved waiver of informed consent or signed informed consent for participation in the retrospective chart review study, if no institutional waiver from the site was granted Exclusion Criteria for Patients in the External Control Arm 1. Malignancy that is not in remission at time of SM diagnosis, or new non-hematological malignancy diagnosed after SM diagnosis, except for: completely resected basal cell and squamous cell skin cancer, curatively treated localized prostate cancer, and completely resected carcinoma in situ of any site 2. Among patients with SM-AHN, presence of either of the following: - Patients in whom the SM component is consistent with an indolent systemic mastocytosis (ISM) or SSM or, - the AHN component is a lymphoid malignancy, or one of the following myeloid malignancies: acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) that is very high-or high-risk as defined by the IPSS-R, or a Philadelphia chromosome positive malignancy or, - there is a known FIP1L1/PDGFRA fusion gene (including those with CHIC-2 deletion and partial deletion of PDGFRA), independent of KIT mutational status 3. Received avapritinib as the first line of systemic therapy for AdvSM at participating site, or prior to initiation of first systemic therapy at participating site. |
Country | Name | City | State |
---|---|---|---|
Austria | Medizinische Universitat Wien | Vienna | |
Germany | Universitatmedizin Mannheim | Mannheim | Baden-Württemberg |
Spain | Hospital Virgen del Valle | Toledo | |
United Kingdom | Guy's and St. Thomas' NHS Foundation Trust | London | England |
United States | Dana Farber Cancer Institute | Boston | Massachusetts |
United States | Standford Cancer Center | Palo Alto | California |
Lead Sponsor | Collaborator |
---|---|
Blueprint Medicines Corporation | Analysis Group, Inc. |
United States, Austria, Germany, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comparative evaluation of overall survival (OS) between patients receiving best available therapy versus avapritinib in BU-285-2101 and BLU-285-2202 | Overall Survival defined as time from initiation of systemic treatment to death from any cause | up to 12 years | |
Secondary | Comparative evaluation between patients receiving best available therapy versus avapritinib of duration of treatment (DOT) | DOT, defined as the duration from initiation of line of systemic treatment to discontinuation of same line of treatment for any reason and; | Up to 12 years | |
Secondary | Comparative evaluation between patients receiving best available therapy versus avapritinib and time to next treatment line (TtNTL) | TtNTL, defined as the time from initiation of the line of systemic treatment to the initiation of the next line of treatment | Up to 12 years | |
Secondary | Comparative evaluation of change in serum tryptase concentration in patients receiving best available therapy versus avapritinib | Change in serum tryptase concentration, defined as change in serum tryptase from baseline, for each line of therapy | Up to 12 years | |
Secondary | To characterize the safety profile and conduct comparative evaluation of safety between patients receiving best available therapy vs. avapritinib | AEs that result in treatment modification or discontinuation, hospitalization, or death according to evaluation of responsible physician | Up to 12 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01807598 -
Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
|
Phase 2 | |
Terminated |
NCT00387426 -
Sunitinib in Treating Patients With Idiopathic Myelofibrosis
|
Phase 2 | |
Completed |
NCT00898079 -
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
|
||
Active, not recruiting |
NCT03580655 -
(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
|
Phase 2 | |
Completed |
NCT00112593 -
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
|
N/A | |
Completed |
NCT00006251 -
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT02415608 -
Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis
|
Phase 2 | |
Active, not recruiting |
NCT00118352 -
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
|
Phase 2 | |
Completed |
NCT02561988 -
(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
|
Phase 1 | |
Completed |
NCT01869777 -
Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia
|
N/A | |
Completed |
NCT01231919 -
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
|
Phase 1 | |
Completed |
NCT01273766 -
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
|
Phase 2 | |
Terminated |
NCT03214666 -
GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT01199562 -
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
|
||
Completed |
NCT00014235 -
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies
|
N/A | |
Completed |
NCT00890747 -
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT01053494 -
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer
|
N/A | |
Available |
NCT05219266 -
Managed Access Programs for PKC412, Midostaurin
|